These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20856685)

  • 41. Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis.
    Alshamrani F; Alnajashi H; Almuaigel MF
    Cureus; 2020 Feb; 12(2):e6995. PubMed ID: 32206459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cladribine tablets: in relapsing-remitting multiple sclerosis.
    Muir VJ; Plosker GL
    CNS Drugs; 2011 Mar; 25(3):239-49. PubMed ID: 21323395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
    Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
    Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
    Oreja-Guevara C; García-Merino JA; Saiz A; Rodríguez-Antigüedad A; Álvarez-Cermeño JC; Estrada-Pérez V; Izquierdo G; Fernández O
    Rev Neurol; 2019 Dec; 69(s02):1-9. PubMed ID: 31933293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM; Rainka MM; Patel MJ; Gengo FM
    Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine.
    Biernacki T; Sandi D; Bencsik K; Vécsei L
    Mini Rev Med Chem; 2020; 20(4):269-285. PubMed ID: 31644403
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Emerging therapies for multiple sclerosis].
    de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A
    Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).
    Patti F; Visconti A; Capacchione A; Roy S; Trojano M;
    Ther Adv Neurol Disord; 2020; 13():1756286420922685. PubMed ID: 32587633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advances in the treatment of relapsing-remitting multiple sclerosis.
    Tanasescu R; Ionete C; Chou IJ; Constantinescu CS
    Biomed J; 2014; 37(2):41-9. PubMed ID: 24732658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis.
    Correale J; Halfon MJ; Jack D; Rubstein A; Villa A
    Mult Scler Relat Disord; 2021 Nov; 56():103264. PubMed ID: 34547609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Laquinimod therapy in multiple sclerosis: a comprehensive review.
    Kolb-Sobieraj C; Gupta S; Weinstock-Guttman B
    Neurol Ther; 2014 Jun; 3(1):29-39. PubMed ID: 26000222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis.
    Tafazzoli A; Chavan A; Harty G; Moller J; Wong SL
    Adv Ther; 2020 Sep; 37(9):3791-3806. PubMed ID: 32647909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
    Pakpoor J; Disanto G; Altmann DR; Pavitt S; Turner BP; Marta M; Juliusson G; Baker D; Chataway J; Schmierer K
    Neurol Neuroimmunol Neuroinflamm; 2015 Dec; 2(6):e158. PubMed ID: 26468472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
    Warnke C; Wiendl H; Hartung HP; Stüve O; Kieseier BC
    Drug Des Devel Ther; 2010 Jul; 4():117-26. PubMed ID: 20689698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals.
    Shephard A; Kolaczkowski L; Barker N; Nahal D; Oreja-Guevara C; Reyes S; Gray H; Salloukh H; Giovannoni G
    Neurol Ther; 2024 Aug; 13(4):1015-1038. PubMed ID: 38760637
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cladribine in the treatment of relapsing multiple sclerosis].
    Robles-Cedeno R; Ramio-Torrenta L
    Rev Neurol; 2018 Nov; 67(9):343-354. PubMed ID: 30350846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.